Commercial landscape of noninvasive prenatal testing in the United States.
Commercial landscape of noninvasive prenatal testing in the United States.
复制标题
DOI:
10.1002/pd.4101
复制
发表时间:
2013-06
影响因子:
3
通讯作者:
Chandrasekharan, Subhashini
中科院分区:
文献类型:
--
作者:
Agarwal, Ashwin;Sayres, Lauren C.;Cho, Mildred K.;Cook-Deegan, Robert;Chandrasekharan, Subhashini
Cell-free fetal DNA-based noninvasive prenatal testing (NIPT) could significantly change the paradigm of prenatal testing and screening. Intellectual property (IP) and commercialization promise to be important components of the emerging debate about clinical implementation of these technologies. We have assembled information about types of testing, prices, turnaround times and reimbursement of recently launched commercial tests in the United States from the trade press, news articles, and scientific, legal, and business publications. We also describe the patenting and licensing landscape of technologies underlying these tests and ongoing patent litigation in the United States. Finally, we discuss how IP issues may affect clinical translation of NIPT and their potential implications for stakeholders. Fetal medicine professionals (clinicians and researchers), genetic counselors, insurers, regulators, test developers and patients may be able to use this information to make informed decisions about clinical implementation of current and emerging noninvasive prenatal tests.
影响因子:
9.8
作者:
Ashoor, Ghalia;Syngelaki, Argyro;Nicolaides, Kypros H.
通讯作者:
Nicolaides, Kypros H.
影响因子:
7.2
作者:
通讯作者:
--
DOI:
10.1097/gim.0b013e3181d68293
发表时间:
2010-04
期刊:
Genetics in medicine : official journal of the American College of Medical Genetics
影响因子:
--
作者:
Angrist M;Chandrasekharan S;Heaney C;Cook-Deegan R
通讯作者:
Cook-Deegan R